Wednesday, July 8, 2026
🇺🇸 FDA

pharma · Dry Eye · Conjunctivitis, Allergic · ALDX

Aldeyra Therapeutics

Aldeyra Therapeutics clinical programs — 26 development programs from ClinicalTrials.gov with phase, modality, indication, and trial identifiers.

Website Investor relations
131 Hartwell Avenue, Suite 320, Lexington, Massachusetts 02421, US HQ
2004 Founded
14 Employees
Public company Type
ALDX · NYSE Ticker
Company details
Status
Public
HQ
131 Hartwell Avenue, Suite 320, Lexington, Massachusetts 02421, US
Founded
2004
Employees
14
Programs
26
Drugs
12
Patents
38
Official website ↗ All projects Drug pipeline Patents News & analysis
Intelligence · Clinical Programs

Aldeyra Therapeutics projects

26 ClinicalTrials.gov programs sponsored by Aldeyra Therapeutics.

Aldeyra Therapeutics has 26 clinical development programs indexed from ClinicalTrials.gov, including phase, modality, indication text, and linked NCT identifiers.

All phases Phase III Phase II Phase I NDA / BLA filed Approved programs

26 programs

Clinical programs

  1. ADX-102 1% Topical Dermal Cream (reproxalap)

    Aldeyra Therapeutics

    Sjogren-Larsson Syndrome

    phase 3 small molecule completed

    1 trial

  2. ADX-102 Ophthalmic Solution (0.5%)

    Aldeyra Therapeutics

    Non-infectious Anterior Uveitis

    phase 3 small molecule completed

    1 trial

  3. ADX-2191 (intravitreal methotrexate 0.8%)

    Aldeyra Therapeutics

    Proliferative Vitreoretinopathy

    phase 3 small molecule completed

    1 trial

  4. ICM ADX-2191 injection

    Aldeyra Therapeutics

    Primary Vitreoretinal Lymphoma

    phase 3 small molecule active

    1 trial

  5. Reproxalap Ophthalmic Solution (0.25%)

    Aldeyra Therapeutics

    Allergic Conjunctivitis

    phase 3 small molecule completed

    4 trials

  6. Reproxalap Ophthalmic Solution (0.25%)

    Aldeyra Therapeutics

    Dry Eye Disease

    phase 3 small molecule completed

    4 trials

  7. Reproxalap Ophthalmic Solution (0.25%)

    Aldeyra Therapeutics

    Dry Eye

    phase 3 small molecule completed

    4 trials

  8. Reproxalap Ophthalmic Solution (0.25%) QID

    Aldeyra Therapeutics

    Dry Eye

    phase 3 small molecule completed

    1 trial

  9. ADX-102 Ophthalmic Drops (0.5%)

    Aldeyra Therapeutics

    Conjunctivitis, Allergic

    phase 2 small molecule completed

    1 trial

  10. ADX-102 Ophthalmic Solution (0.5%)

    Aldeyra Therapeutics

    Dry Eye Syndromes

    phase 2 small molecule completed

    1 trial

  11. ADX-2191

    Aldeyra Therapeutics

    Retinitis Pigmentosa

    phase 2 small molecule completed

    1 trial

  12. ADX-629

    Aldeyra Therapeutics

    Ethanol Intoxication

    phase 2 small molecule completed

    1 trial

  13. ADX-629

    Aldeyra Therapeutics

    Alcohol Hepatitis

    phase 2 small molecule completed

    1 trial

  14. ADX-629

    Aldeyra Therapeutics

    Plaque Psoriasis

    phase 2 small molecule completed

    1 trial

  15. ADX-629

    Aldeyra Therapeutics

    Nephrotic Syndrome

    phase 2 small molecule terminated

    1 trial

  16. ADX-629

    Aldeyra Therapeutics

    Atopic Asthma

    phase 2 small molecule completed

    1 trial

  17. ADX-629

    Aldeyra Therapeutics

    Chronic Cough

    phase 2 small molecule completed

    1 trial

  18. ADX-629

    Aldeyra Therapeutics

    Covid19

    phase 2 small molecule completed

    1 trial

  19. ADX-629 (Open-label)

    Aldeyra Therapeutics

    Atopic Dermatitis

    phase 2 small molecule completed

    1 trial

  20. Active topical NS2 1% dermatologic cream

    Aldeyra Therapeutics

    Sjögren-Larsson Syndrome

    phase 2 small molecule completed

    1 trial

  21. NS2

    Aldeyra Therapeutics

    Non-infectious Anterior Uveitis

    phase 2 small molecule completed

    1 trial

  22. NS2 Ophthalmic Drops (0.5%)

    Aldeyra Therapeutics

    Allergic Conjunctivitis

    phase 2 small molecule completed

    1 trial

  23. Reproxalap Ophthalmic Solution (0.25% Novel Formulation) QID to BID

    Aldeyra Therapeutics

    Dry Eye

    phase 2 small molecule completed

    1 trial

  24. Reproxalap Ophthalmic Solution (0.25%)

    Aldeyra Therapeutics

    Dry Eye Syndrome

    phase 2 small molecule completed

    1 trial

  25. Reproxalap Ophthalmic Solution (0.25%)

    Aldeyra Therapeutics

    Conjunctivitis, Allergic

    phase 2 small molecule completed

    1 trial

  26. Reproxalap Ophthalmic Solution (0.25%)

    Aldeyra Therapeutics

    Dry Eye Syndromes

    phase 2 small molecule completed

    1 trial

Frequently asked questions

How many clinical projects does Aldeyra Therapeutics have?

26 published programs are linked to this sponsor in our ClinicalTrials.gov index.

Is this the complete company pipeline?

This directory lists published programs for the sponsor in our database. Partnered or out-licensed assets may appear under multiple companies.

Drug approvals, clinical trials, M&A, event intelligence, and company updates — weekly.

Customize topics & region
Topics
Region

No spam. Unsubscribe anytime. See our privacy policy.